Diabetes tracker developer Dexcom is pushing back the timeline for a U.S. launch of the latest generation of its continuous glucose monitor, the G7, after the FDA raised questions about the device’s ...
The CGM provides real-time glucose readings for 15.5 days. “As a disabled veteran living with Type 2 diabetes, becoming a grandfather has given me a powerful new reason to take charge of my health,” ...
One of our favorite CGM systems is getting an upgrade. The G7 is smaller than the G6, takes less time to warm up and comes with an improved app and alerts. Jessica was a writer on the Wellness team, ...
Dexcom announced last week that its G7 continuous glucose monitoring system has received FDA clearance. The latest model of its CGM, which can be used by people with all types of diabetes ages 2 and ...
Tandem Diabetes Care, Inc. TNDM recently launched the updated t:slim X2 insulin pump software with Dexcom G7 Continuous Glucose Monitoring (“CGM”) integration in the United States. This marks the ...
SAN DIEGO & EDINBURGH, Scotland--(BUSINESS WIRE)--DexCom, Inc. (Nasdaq: DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today the Dexcom G7 ...
In this week's episode of the Homekit Insider podcast, your hosts review the new Sonos Sub Mini, discuss what the Matter 1.0 certification means, and more! Leading off the show, the Connectivity ...
DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, announced today the Dexcom G7 15 Day Continuous Glucose Monitoring (CGM) System for people over the age of 18 with diabetes will ...
DexCom Inc. (NASDAQ:DXCM) is one of the best growth stocks to buy in 2026. On December 2, Morgan Stanley upgraded DexCom to Overweight from Equal Weight with a price target of $75, which was up from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback